<DOC>
	<DOCNO>NCT00006368</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled drug yttrium Y 90 SMT 487 locate tumor cell deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness yttrium Y 90 SMT 487 treat patient refractory recurrent cancer .</brief_summary>
	<brief_title>Yttrium Y 90 SMT 487 Treating Patients With Refractory Recurrent Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose yttrium Y 90-SMT 487 patient recurrent malignant neoplasm prove positive somatostatin receptor . II . Determine safety lifetime serious adverse event profile regimen patient . II . Determine antitumor effect effect repeat administration renal excretion pharmacokinetics regimen patient . OUTLINE : This dose escalation , multicenter study . Patients undergo octreotide scintigraphy determine location somatostatin receptor . Patients receive yttrium Y 90-SMT 487 IV 15 minute day 1 . Treatment continue every 6 week 4 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient enter course I ( vertical dose escalation ) course II , III , IV ( horizontal dose escalation ) . Cohorts receive escalate dos yttrium Y 90-SMT 487 maximum tolerate dose ( MTD ) determine . MTDs determine single course 4 course . The MTD define dose precede 2 6 patient experience dose limit toxicity . Results course I determine dosage subsequent course . Patients evaluate day 2 7 , week 4 6 , follow injection yttrium Y 90-SMT 487 . Patients follow 12 18 month annually thereafter . PROJECTED ACCRUAL : Approximately 20 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Edotreotide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm , progressive malignant neoplasm Clinical diagnosis multiple endocrine neoplasia ( MEN ) type I II allow Tumors positive somatostatin receptor octreotide scintigraphy , : Pituitary Brain Endocrine pancreatic Lymphoma Carcinoid Melanoma Small cell lung Breast Disease amenable standard treatment OR Failed exist first second line therapy ( fail least 1 regimen case small cell lung cancer ) Bone disease ( diffuse bone marrow involvement ) , pleural effusion , ascites allow PATIENT CHARACTERISTICS : Age : 18 Performance status : Course I : Karnofsky 50100 % Courses IIIV : Karnofsky 30100 % Life expectancy : At least 6 month great 2.5 year ( course I ) Hematopoietic : Course I : Hemoglobin least 8 g/dL WBC least 3,500/mm3 Platelet count least 100,000/mm3 Courses IIIV : WBC least 3,000/mm3 Platelet count least 75,000/mm3 Hepatic : Not specify Renal : Creatinine great 1.7 mg/dL OR Creatinine clearance least 40 mL/min Cardiovascular : No history congestive heart failure unless ejection fraction least 40 % Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study No concurrent malignancy except MEN I II squamous cell skin cancer No concurrent significant , uncontrolled , medical , psychiatric , surgical condition would preclude study ( course 1 ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy Greater 4 week since prior chemotherapy Endocrine therapy : At least 4 month since prior long act somatostatin analogue Concurrent hormonal therapy ( except somatostatin analogue ) allow start least 2 month previously Radiotherapy : Greater 4 week since prior radiotherapy No prior radiotherapy least 25 % bone marrow Surgery : Greater 4 week since prior surgery Other : Greater 4 week since prior investigational drug No concurrent investigational drug therapy No concurrent antineoplastic therapy Concurrent bisphosphonates allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>gastrinoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>insulinoma</keyword>
	<keyword>recurrent islet cell carcinoma</keyword>
	<keyword>ACTH-producing pituitary tumor</keyword>
	<keyword>prolactin-producing pituitary tumor</keyword>
	<keyword>growth hormone-producing pituitary tumor</keyword>
	<keyword>recurrent pituitary tumor</keyword>
	<keyword>TSH produce pituitary tumor</keyword>
	<keyword>nonfunctioning pituitary tumor</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult craniopharyngioma</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult meningioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>WDHA syndrome</keyword>
	<keyword>somatostatinoma</keyword>
	<keyword>pancreatic polypeptide tumor</keyword>
	<keyword>glucagonoma</keyword>
	<keyword>pulmonary carcinoid tumor</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>adult pineocytoma</keyword>
	<keyword>adult pineoblastoma</keyword>
	<keyword>adult meningeal hemangiopericytoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>adult choroid plexus tumor</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult grade III meningioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>